Our Grants
| GRANTS | DATE | AMOUNT | PROGRAM |
|---|---|---|---|
| The Regents of the University of Colorado, Denver Prenatal and Obstetric Maternal Exposures and Islet Autoimmunity in Early Life (PROMISE) | 10.25.2022 | $3,000,000 | Type 1 Diabetes, Prevent & Delay |
| Region Hovedstaden Can microchimerism explain differences in parental type 1 diabetes conferred risk of offspring type 1 diabetes? | 10.25.2022 | $592,935 | Type 1 Diabetes, Prevent & Delay |
| King’s College London Characterising ‘NoGo Autoimmunity’ in genetically protected (HLA-DQ6+) subjects | 10.25.2022 | $757,700 | Type 1 Diabetes, Prevent & Delay |
| King’s College London Prenatal drivers of infant ISlet Autoimmunity (PISA study) | 10.25.2022 | $2,422,655 | Type 1 Diabetes, Prevent & Delay |
| Kyler Cares Foundation General Operating Support | 10.25.2022 | $150,000 | Type 1 Diabetes, Improve Outcomes |
| The Baruch Padeh Medical Center, Poriya Robotic Assisted Surgery - Purchase of a surgical robot | 10.25.2022 | $2,500,000 | Israel, Healthcare & Preparedness |
| Foundation for Innovative New Diagnostics FIND ACess to CGMs for Equity in DiabEtes management - The ACCEDE project | 10.25.2022 | $3,513,213 | Type 1 Diabetes, Improve Outcomes |
| Hillel Yaffe Medical Center Eye Institute and Ambulatory Surgery Center | 10.25.2022 | $5,914,700 | Israel, Healthcare & Preparedness |
| Oregon Health & Science University An MDI Decision Support System with CDCES and Behavioral Health Support | 10.25.2022 | $4,364,007 | Type 1 Diabetes, Improve Outcomes |
| JDRF T1D Fund, LLC T1D Fund Initiative to Drive Pharma Investment in T1D | 10.25.2022 | $1,000,000 | Type 1 Diabetes, Improve Outcomes |
| NCD Alliance 2023-2025 Partnership | 10.25.2022 | $5,902,875 | Type 1 Diabetes, Improve Outcomes |
| The University of Manchester A map of the intestine following regulatory T cell infusion into patients with active Crohn’s Disease at single-cell and spatial resolution | 10.25.2022 | $2,984,681 | Crohn's Disease, Disease Biology |
| Geisinger Clinic Study of pre-implementation outcomes required to implement preventive screening at well-child visits | 10.12.2022 | $701,056 | Type 1 Diabetes, Prevent & Delay |
| Vanderbilt University Medical Center Defining molecular mechanisms of α cell dysfunction in type 1 diabetes to develop new approaches to prevent hypoglycemia | 10.12.2022 | $825,000 | Type 1 Diabetes, Prevent & Delay |
| INNODIA INNODIA Nonprofit Launch | 10.12.2022 | $1,189,643 | Type 1 Diabetes, Prevent & Delay |
| Research Triangle Institute Using Genome Sequencing and Genetic Risk Scores to Identify Newborns with Serious Health Conditions: A Statewide Implementation Study | 10.12.2022 | $3,109,310 | Type 1 Diabetes, Prevent & Delay |
| Civica Foundation Affordable insulin | 09.27.2022 | $5,000,000 | Type 1 Diabetes, Improve Outcomes |
| Vanderbilt University Normalizing hypoglycemia-induced glucagon secretion in T1D through pharmacological restoration of alpha-cell calcium handling | 09.27.2022 | $825,000 | Type 1 Diabetes, Prevent & Delay |
| The Regents of the University of California, San Diego Mechanism of Action and Safety Study of Liver Targeted Insulin | 09.27.2022 | $2,032,393 | Type 1 Diabetes, Improve Outcomes |
| Shaare Zedek Medical Center Upgraded PET-CT scanner utilizing new technological developments for more accurate, quicker and safer diagnosis and monitoring. | 09.27.2022 | $2,700,000 | Israel, Healthcare & Preparedness |
|
You can filter rows:
| |||